FDA Tells Watson, Swedish Drugmaker To Pull Misleading Ads

Law360, New York (June 22, 2012, 7:12 PM ET) -- The U.S. Food and Drug Administration told Watson Pharmaceuticals Inc. and Swedish Orphan Biovitrum AB to stop publishing allegedly misleading advertisements for their anemia treatment and cancer-related mucositis drugs, respectively, according to letters made public Thursday.

In letters dated June 7, the FDA told Watson that a journal ad for its Nulecit anemia treatment makes unsubstantiated claims, while warning Sobi that its ads for Kepivance, a drug that helps people regenerate cells in the mouth and intestinal tract during cancer treatment, omit certain risk information while...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required